CHAMBER OF COMMERCE ISRAEL - UKRAINE’s Post

We tracked 11 orthopedic company funding announcements in 2Q. The #startups will use the capital to conduct clinical trials and expand commercialization efforts across #orthopedics. The raises included: ▪ Integrity Orthopaedics - $20.6 million Series B ▪ Locate Bio Ltd - oversubscribed $11.5 million funding round ▪ Miach Orthopaedics, Inc. - $20 million Series B extension ▪ Nanochon - $4 million seed investment ▪ Osteal Therapeutics - oversubscribed $50 million Series D ▪ restor3d - $55 million Series A ▪ ReVivo Medical, Inc. - $1.3 million from current investors ▪ SLAM Orthopedic - $2.15 million seed investment ▪ SpinEM Robotics SAS - $11 million Series A2 ▪ Theradaptive - $1 million grant ▪ Viseon Inc. - insider financing round https://lnkd.in/eiSjpyKu #funding #medicaldevice

Great news from the German market! Protembis GmbH has received s €20 million investment from The European Investment Bank. The funding is to support clinical trials, research, development and market access for the “ProtEmbo” cerebral embolic protection system. TAVR is an x-ray guided procedure to replace an aortic valve that has narrowed and doesn't open fully. TAVR is minimally invasive, meaning it uses smaller incisions than open-heart valve surgery. Globally, around 430,000 patients with severe aortic stenosis are expected to be treated with TAVR by 2025. ProtEmbo is inserted during TAVR via the artery in the left wrist, and lines the roof of the aortic arch, shielding the brain from the dislodged debris. #medtech #healthinnovation #europeaninvestments

Devices we have helped bring to market 😁 🏆 Whilst we like to keep our clients confidential 😉 , here are some of the cool devices we have helped bring to market: -       An artificial intelligence device used in breast cancer screening decisions -       A non-surgical gastric balloon device requiring no anaesthesia or endoscopy -       A haemostatic patch to stop disruptive bleeding during surgery -       Lateral flows, PCRs and LAMP devices for Covid-19 testing -       Insulin pumps including software -       Hip implants and instrumentation -       Ostomy pouches -       Loads of cardiovascular catheters such as balloon dilatation catheters, ECG machines, PICCs, CVCs, haemodialysis catheters and stent grafts. I love seeing the hard work come together and see manufacturers problems solved and devices move from initial conception to commercialisation 😊 Russell Regulatory Consultants #medicaldevices #consultancy #startup #biotech #medtech

Our review of #orthopedic funding announcements in 1Q24 found familiar companies and well-backed markets like #spine, #robotics and #navigation received financial support. Medical Microinstruments, Inc. closed a Series C to support the commercialization of its robotic technology. Carlsmed closed a Series C to support the commercialization and further development of its personalized spine surgery platform. Synergy Spine Solutions raised equity financing to support clinical trials for its artificial disc. icotec raised growth financing to support the development of spine oncology implants. Accelus received a debt facility to accelerate growth of its expandable interbody fusion systems. Pixee Medical secured a capital raise to expand its presence in the U.S. and Asia Pacific. Bone Biologics completed an IPO to fund clinical trials and portfolio support. HAVENTURE startups raised funds to support the development of robotic technologies. Bolt Navigation closed a Series B to support commercialization efforts in the U.S. and EU. MotioOV received investments from OrthoVentions for its metatarsophalangeal joint implant. Check out the full recap. https://lnkd.in/eqr7mU_m #startups #funding #newtech

#fundingalert 💼Company: Protembis GmbH  💰Funding: €30 Million  ⚡Round: Series B 👥Investors:  Segulah Medical Acceleration, XGEN Venture SGR S.p.A., coparion, TechVision Fund. Protembis stands out as a notable player within the dynamic German startup ecosystem. This innovative heart surgery device (the ProtEmbo® Cerebral Protection System) is an intra-aortic filter device that protects the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). This round was use to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). It is a low-profile non thrombogenic system that shields all cerebral vessels, delivered through the left radial artery for optimal placement and stability. Karl von Mangoldt Conrad Rasmus Oliver Schumacher Nawzer Mehta James Hallums Read more - https://lnkd.in/gbHHt9nq To share your startup story write us on - contact@startuprise.co.uk #Protembis #healthtech #medtech #germanstartupecosystem #innovation #cardiovascular #heartdevice #funding #startupnews #fundingnews #news #germanstartup

VIEW | Despite progression in advanced treatments for malignant tumors, surgery remains the primary treatment intervention, which removes a large portion of firm tumor tissues; however, the postoperative phase poses a possible risk for provincial tumor recurrence and metastasis. Consequently, the prevention of tumor recurrence and metastasis has attracted research attention. For full review, please view: https://lnkd.in/gSGBZiZ9 About VIEW journal📑 #VIEW is a high-quality, interdisciplinary, and rapid-publication open access journal focusing on “biodiagnostics” in the field of biomaterials. From in vitro to in vivo, small to mega, fundamentals to application, with an emphasis on the biomaterials used particularly in biotechnology and medicine.

🚀 HistoSonics, Inc. Secures $102M Series D Funding, Paving the Way for a New Era in Non-Invasive Surgery 🚀 Histotripsy is a technology that uses sound energy to precisely target and destroy tissue without incisions, radiation, or heat. This means patients can undergo treatment with minimal recovery time, reducing the risks and complications associated with other surgical methods. Their Edison platform is very impressive and at SRS earlier this year the booth was a crowded place with an impressive demo. As the global population ages, the demand for less invasive, more precise treatment options is only increasing. HistoSonics is answering this call with a technology that not only improves patient outcomes but also allows the surgeon to treat a wider variety of tumor types in the liver, kidney, pancreas, prostate, and even brain tumors. “Histotripsy is a paradigm-changing treatment option for patients who want a non-invasive approach to target and destroy tumors without the need for needles or incisions,” said Mike Blue, President & CEO, HistoSonics. “We’re thrilled to announce this top-tier investor syndicate led by Alpha Wave, which reinforces the confidence in our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. With Alpha Wave Ventures leading the round, with support from Johnson & Johnson Innovation JJDC Inc, Amzak Capital Management and HealthQuest Capital. 🎉 Congratulations to the HistoSonics team on this funding.🎉 #medtech #noninvasivesurgery #innovation #investment #histotripsy #medicaltechnology

Check out this Glaucoma Today article and see what Dr. Arsham Sheybani thinks of modulating aqueous flow with the Calibreye™ Titratable Glaucoma Therapy™ Surgical System.   https://lnkd.in/ef6bxKBx #glaucoma #IOP #innovation #startup #makingadifference

The applications of nanomaterials in medical devices have brought significant advancements in biocompatibility and functionality. Nanorobots, nanochips, and nanoimplants are enhancing tissue substitutes, regeneration, prostheses, and cell repair, revolutionizing surgery with reduced neighboring tissue/cell damage. Nanorobots offer hope for early cancer diagnosis and targeted drug delivery. Improved implants promise cost reduction, ease of use, and fewer side effects for patients. Ongoing research is developing various nanomedical devices for better diagnosis and therapeutics, ultimately enhancing human quality of life. While many applications are in the laboratory, some are already in clinical use, indicating a promising future with further research and prototypes. #snsintitutions #snsdesignthinkers #designthinking

💲𝐕𝐢𝐚𝐋𝐚𝐬𝐞 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $40𝐌 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐟𝐨𝐫 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐚𝐫𝐲 𝐆𝐥𝐚𝐮𝐜𝐨𝐦𝐚 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 🚀ViaLase, Inc, a pioneering medical technology company, has achieved a significant milestone in ophthalmology with the completion of a Series C financing round, raising an impressive $40 million. This funding is set to accelerate the development, regulatory approval, and commercialisation efforts of the ViaLase Laser, a groundbreaking device designed for the treatment of primary open-angle glaucoma. 👁Glaucoma, particularly primary open-angle glaucoma, poses a significant health challenge globally, affecting millions of individuals. Traditional treatments often involve invasive procedures and medication regimens. However, ViaLase aims to redefine glaucoma management with its innovative femtosecond laser technology. 👩⚕️The ViaLase Laser is the first femtosecond laser engineered specifically for glaucoma treatment. It offers a promising new approach through femtosecond laser image-guided high-precision trabeculotomy (FLigHT), a non-invasive procedure providing unparalleled precision and visibility for reducing intraocular pressure. Unlike traditional surgeries, FLigHT promises precise outcomes without associated risks and lengthy recovery times. 💉The financing round underscores investors’ confidence in Vialase’s innovative approach and the potential impact of its technology. As ViaLase accelerates development efforts, moves closer to regulatory approval, and prepares for commercialisation, the future holds promise for patients seeking effective and minimally invasive solutions for glaucoma management. With the ViaLase Laser on the horizon, there’s hope for improved patient outcomes and enhanced quality of life in the realm of ophthalmic care.